St George's Hospital, London, United Kingdom.
John Radcliffe Hospital, Oxford, United Kingdom.
J Orthop Trauma. 2022 Sep 1;36(9):e343-e348. doi: 10.1097/BOT.0000000000002368.
(1) Evaluate whether initial results from percutaneous treatment of nonunion are reproducible (2) Estimate the relative cost of percutaneous treatment of nonunion versus traditional methods.
Retrospective multicentre case series.
Four Level 1 trauma centers.
PATIENTS/PARTICIPANTS: Fifty-one patients (34 men and 17 women) with a median age of 51 years (range 14-81) were treated for nonunion at a median of 10 months (range 4-212) from injury.
Percutaneous strain reduction screws (PSRS).
Union rates and time to union were compared for patients treated in the developing institution versus independent units as well as with previously published results.
Forty-five (88%) patients achieved union at a median time of 5.2 months (range 1.0-24.7) confirming the previously published results for this technique. Comparable results were seen between the developing institution and independent units. No patients experienced adverse events beyond failure to achieve union. PSRS seems to offer savings of between £3177 ($4416) to £11,352 ($15,780) per case compared with traditional methods of nonunion surgery.
PSRS is a safe, efficacious treatment for long bone nonunion and may be more cost-effective than traditional nonunion treatment methods. The promising initial results of this technique have now been replicated outside of the developing institution.
Therapeutic Level IV. See Instructions for Authors for a complete description of levels of evidence.
(1) 评估经皮治疗骨不连的初始结果是否可重现;(2) 估计经皮治疗骨不连与传统方法的相对成本。
回顾性多中心病例系列。
四家 1 级创伤中心。
患者/参与者:51 名患者(34 名男性和 17 名女性),中位年龄为 51 岁(范围 14-81 岁),受伤后中位数为 10 个月(范围 4-212 个月)接受骨不连治疗。
经皮应变减轻螺钉(PSRS)。
比较在发展机构与独立单位治疗的患者以及与先前发表的结果的愈合率和愈合时间。
45 名(88%)患者在中位数为 5.2 个月(范围 1.0-24.7)的时间内实现了愈合,证实了该技术先前发表的结果。发展机构和独立单位之间的结果相似。没有患者发生除未能愈合之外的不良事件。PSRS 似乎比传统的非愈合手术方法每例节省 3177 英镑(4416 美元)至 11352 英镑(15780 美元)。
PSRS 是治疗长骨骨不连的一种安全、有效的方法,并且可能比传统的非愈合治疗方法更具成本效益。该技术的初步结果令人鼓舞,现已在发展机构之外得到复制。
治疗性 IV 级。请参阅作者说明,以获取完整的证据水平描述。